Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer-Reference-Cited by-同舟云学术

Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer

Published:2018-06-15 Issue:1 Volume:37 Page:155-163
ISSN:0724-4983
Container-title:World Journal of Urology
language:en
Short-container-title:World J Urol

Author:

Thiel Tomas^ORCID,Ryk Charlotta,Renström-Koskela Lotta,Steineck Gunnar,Schumacher Martin C.,Wiklund N. Peter,de Verdier Petra J.

Funder

Cancerföreningen i Stockholm

Publisher

Springer Science and Business Media LLC

Subject

Urology

Link

http://link.springer.com/article/10.1007/s00345-018-2375-7/fulltext.html

Reference26 articles.

1. Morales A, Eidinger D, Bruce AW (1976) Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumours. J Urol 116(2):180–183

2. Babjuk M, Oosterlinck W, Sylvester R et al (2011) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59(6):997–1008

3. Babjuk M, Burger M, Zigeuner R et al (2013) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64(4):639–653

4. Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466–477 (discussion 475–467)

5. Larsson P, Wijkstrom H, Thorstenson A et al (2003) A population-based study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years. Scand J Urol Nephrol 37(3):195–201

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. “Glycans in Trained Immunity: Educators of innate immune memory in homeostasis and disease”;Carbohydrate Research;2024-10

2. Revolutionizing Treatment: Breakthrough Approaches for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer;Cancers;2024-03-30

3. Intra-arterial chemotherapy plus BCG, a promising combination adjuvant treatment for high-risk NMIBC;Urologic Oncology: Seminars and Original Investigations;2023-10

4. Preoperative systemic inflammation response index is an independent prognostic marker for BCG immunotherapy in patients with non‐muscle‐invasive bladder cancer;Cancer Medicine;2022-10-10

5. Comparative efficacy of intravesical perfusion therapy in non-muscle invasive bladder cancer : A systematic review and network meta-analysis;2022-08-24